Management of Chronic Hepatitis C Virus Infection: A Consensus Report of the Study Group for Viral Hepatitis of the Turkish Society of Clinical Microbiology and Infectious Diseases-2017 Update

Aygen, Bilgehan; Demirtürk, Neşe; Türker, Nesrin; Aşan, Ali; Eraksoy, Haluk; Gürbüz, Yunus; İnan, Dilara; Keten, Derya; Koçulu, Safiye; Öncü, Serkan; Ozkaya, Deniz; Saltoğlu, Neşe; Sayan, Murat; Süer, Kaya; Şener, Alper; Tekin, Süda Koruk; Tuna, Nazan; Yazıcı, Saadet

doi:10.5152/kd.2017.12

Cited by 9 publications

(11 citation statements)

References 116 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The indications for HCV testing (abnormal liver tests, suspected sexual contact, intravenous drug abuse, receiving hemodialysis or donated blood or organs, long-term hospitalization, surgical operation, etc.) and laboratory methods for the diagnosis of HCV infection were generally determined according to the current published guidelines [4,5,7]. All patients with suspected HCV infection were evaluated for HBV and HIV coinfections.…”

Section: Methodsmentioning

confidence: 99%

“…Hepatitis C virus (HCV) infection is a major public health problem affecting over 200 million people globally [1,2]. In Turkey, the prevalence of HCV infection is reported as 0.3-1.8%, and approximately 600.000 individuals are estimated to be infected with HCV [3][4][5]. The most common HCV genotype in our country is genotype 1b [2,4].…”

Section: Introductionmentioning

confidence: 99%

“…In Turkey, the prevalence of HCV infection is reported as 0.3-1.8%, and approximately 600.000 individuals are estimated to be infected with HCV [3][4][5]. The most common HCV genotype in our country is genotype 1b [2,4]. Until the beginning of 2010s, the standard treatment of chronic HCV infection has been based on the combination antiviral therapy with pegylated interferon alfa and ribavirin.…”

Section: Introductionmentioning

confidence: 99%

“…In recent years, direct-acting antivirals, including secondgeneration NS3-4A protease inhibitors, NS5A inhibitors, and NS5B polymerase inhibitors have been launched, and have improved treatment options for HCV infection dramatically [6]. Current standard therapies in our country are applied according to the published guidelines in Europe and Turkey [4,5,7]. There are differences in the recommended regimens depending on the HCV genotype, the presence/absence of resistance-associated substitutions or compensated cirrhosis.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Evaluation of biochemical, hematological, RIBA and PCR assays in predicting viremia in anti-HCV positive patients

Şirin

Arıdoğan

Çetin

et al. 2019

J Infect Dev Ctries

View full text Add to dashboard Cite

Introduction: The detection of HCV-RNA by PCR assays is considered to be the gold standard for confirming the presence of HCV viremia. However, high costs, long and laborious procedures limit their widespread usage. This retrospective study was conducted to assess the predictive performances of biochemical and hematological parameters, anti-HCV signal-to-cutoff (S/CO) ratios and RIBA assay for HCV viremia. Methodology: Medical records of 210 patients with positive anti-HCV results were analyzed. Samples were tested for anti-HCV by the Roche Elecsys assay. RIBA and PCR assays were performed with Inno-Lia HCV Score test, and Roche Cobas TaqMan HCV test, respectively. Results: Anti-HCV positive patients were categorized into two groups: positive HCV-RNA(viremic) group (n = 94) and negative HCV-RNA(non-viremic) group (n = 116). All viremic patients had positive RIBA results, while in the non-viremic group, 80 (69%) patients had negative/indeterminate RIBA results and 36 (31%) patients had positive RIBA results. Compared with the non-viremic group, the viremic group had significantly higher alanine aminotransaminase (ALT), aspartate aminotransferase, gamma-glutamyl transferase, mean platelet volume, platelet distribution width and anti-HCV levels, and significantly lower platelet count and plateletcrit levels (p < 0.05). With multivariate logistic regression analysis, serum ALT and anti-HCV levels were found to be strong predictive factors for HCV viremia. A S/CO ratio of ≥ 12.34 was identified as the optimal anti-HCV level to predict viremia. Conclusions: An anti-HCV S/CO ratio of 12.34 can determine the necessity for PCR assay, when carefully evaluated together with the biochemical and hematological evidence. This approach may reduce the cost of diagnosis particularly in low-resource settings.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Evaluation of biochemical, hematological, RIBA and PCR assays in predicting viremia in anti-HCV positive patients

Şirin

Arıdoğan

Çetin

et al. 2019

J Infect Dev Ctries

View full text Add to dashboard Cite

show abstract

“…Guidelines recommend a combination of glecaprevir/pibrentasvir, grazoprevir/elbasvir, and ritonavir-fortified paritaprevir, ombitasvir, and dasabuvir (3D regimen) for the treatment of CHC patients undergoing hemodialysis due to severe kidney disease (creatinine clearance ≤30 ml/min) or end-stage kidney disease [9] . Guidelines from Turkey also state that the 3D regimen can be used in this patient group without the need for dose adjustment [10,11] . The aim of this study was to evaluate the efficacy and safety of the 3D regimen for the treatment of CHC in hemodialysis patients.…”

Section: Introductionmentioning

confidence: 99%

Efficacy and Safety of the Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir Regimen for Chronic Hepatitis C in Hemodialysis Patients

Tosun¹,

Sultanova²,

Ak³

et al. 2019

mjima

View full text Add to dashboard Cite

Introduction: A higher percentage of sustained virologic response (SVR) has been reported with the introduction of direct-acting antivirals (DAAs) to the treatment of hepatitis C in recent years. However, there are still relatively limited data on the effectiveness and safety of the use of DAAs in hemodialysis patients. The aim of this study was to evaluate the efficacy and safety of chronic hepatitis C treatment with paritaprevir/ritonavir/ ombitasvir and dasabuvir (3D) in hemodialysis patients. Materials and Methods: Hemodialysis patients who were treated with 3D regimen between July 2016 and October 2018 were evaluated retrospectively. Patients coinfected with hepatitis B or human immunodeficiency virus and those with cirrhosis were excluded. Serum hepatitis C virus (HCV) RNA and alanine aminotransferase levels of the patients were recorded after one and three months of therapy. SVR was defined as negative HCV RNA at three months after cessation of HCV treatment. Any drug-related alterations in clinical or laboratory findings during the treatment period were evaluated as side effects. Results: Fifteen patients who were treated with the 3D regimen during the study period were included. Genotype 1b and 1a were detected in 12 and three patients, respectively. Ribavirin was added to treatment for genotype 1a-infected patients. Hemoglobin levels were reduced in two of the three patients who received ribavirin. One patient had macular rash and another patient complained of fatigue. No serious side effects were observed. At the end of treatment, a low level of HCV RNA (63 IU/ml) was detected in only one patient. At the end of treatment, HCV RNA negativity was achieved in 12 out of 13 patients whose HCV RNA quantitation data were available. End-of-treatment success rate was 92%. SVR was achieved in all of the patients at three-months after treatment cessation (100% SVR12). Conclusion: This study shows that the 3D regimen is safe and effective in the treatment of hemodialysis patients infected with hepatitis C.

show abstract

Elektif göz cerrahisi öncesi hepatit B, hepatit C ve insan immün yetmezlik virüsü tarama sonuçlarının değerlendirilmesi

Türkoğlu

Konuk

2022

Mustafa Kemal Üniversitesi Tıp Dergisi

View full text Add to dashboard Cite

Objective: Although preoperative screening for Hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV) infections in patients is a controversial issue in terms of cost-effectiveness and patient privacy, this practice is commonly carried on by surgical branches. The goals of this study were to evaluate the prevalence of preoperative HBV surface antigen (HBsAg), anti-HCV and anti-HIV antibodies, as well as whether seropositive patients were referred to the infectious diseases outpatient clinic. Methods: In this study, blood samples from 884 patients who underwent elective eye surgery at Tokat Gaziosmanpasa University Medical Faculty Hospital between August 2019 and April 2021 were researched for HBsAg, anti-HCV and anti-HIV positivity and seroprevalences were determined. It was also determined whether patients with seropositivity from the hospital automation system had previously been diagnosed and if newly diagnosed patients applied to the infectious diseases outpatient clinic in the subsequent period. Results: The study comprised a total of 884 patients. Males comprised 457 (51.7%) of all patients, with a mean age of 63.21± 16.05. In 29/839 (3.3%) of the patients, HBsAg was positive. Anti-HCV positivity was found in 21/872 (2.4%) people. Anti-HIV positivity was not detected in any of the patients. Conclusion: It would be a more accurate and effective approach to increase compliance with standard hygiene and protection measures rather than requesting routine pre-operative testing for HBV, HCV and HIV. If these tests reveal seropositivity, the patient should be informed of the disease and referred to an infectious disease specialist.

show abstract

Management of Chronic Hepatitis C Virus Infection: A Consensus Report of the Study Group for Viral Hepatitis of the Turkish Society of Clinical Microbiology and Infectious Diseases-2017 Update

Cited by 9 publications

References 116 publications

Evaluation of biochemical, hematological, RIBA and PCR assays in predicting viremia in anti-HCV positive patients

Evaluation of biochemical, hematological, RIBA and PCR assays in predicting viremia in anti-HCV positive patients

Efficacy and Safety of the Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir Regimen for Chronic Hepatitis C in Hemodialysis Patients

Elektif göz cerrahisi öncesi hepatit B, hepatit C ve insan immün yetmezlik virüsü tarama sonuçlarının değerlendirilmesi

Contact Info

Product

Resources

About